HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rose, M. R. Articles by Griggs, R. C. Search for Related Content PubMed PubMed Citation Articles by Rose, M. R. Articles by Griggs, R. C. Related Collections All Clinical trials

A prospective natural history study of inclusion body myositis

Implications for clinical trials

From the Department of Neurology, King’s Neurosciences Centre, King’s College Hospital, London, UK (Dr. Rose); and Department of Neurology, University of Rochester Medical Center, NY (Drs. McDermott, Thornton, Martens, Griggs, and C. Palenski).

Address correspondence and reprint requests to Dr. M.R. Rose, Department of Neurology, King’s Neurosciences Centre, King’s College Hospital, Denmark Hill, London, UK SE5 9RS; e-mail: m.r.rose{at}kcl.ac.uk

Eleven patients with untreated inclusion body myositis (IBM) were prospectively studied during a 6-month period that included muscle strength, lean body mass, and muscle mass measurements. There was an overall quantifiable mean decline in percent of predicted normal muscle strength of 4% from baseline in a 6-month period, but one third of patients showed no change or slight improvements in strength. Short-term treatment trials in IBM will require large numbers of patients to detect slowing, arrest, or even slight improvement in muscle strength.

This article has been cited by other articles:

				J. Kota, C. R. Handy, A. M. Haidet, C. L. Montgomery, A. Eagle, L. R. Rodino-Klapac, D. Tucker, C. J. Shilling, W. R. Therlfall, C. M. Walker, et al. Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates Science Translational Medicine, November 11, 2009; 1(6): 6ra15 - 6ra15. [Abstract] [Full Text] [PDF]

				M. C. Dalakas, G. Rakocevic, J. Schmidt, B. McElroy, M. O. Harris-Love, J. A. Shrader, E. W. Levy, and J. Dambrosia Reply to: Comment on alemtuzumab and inclusion body myositis Brain, November 5, 2009; (2009) awp276v1. [Full Text] [PDF]

				N. Chahin and A. G. Engel Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM Neurology, February 5, 2008; 70(6): 418 - 424. [Abstract] [Full Text] [PDF]

				R. C. Griggs The current status of treatment for inclusion-body myositis Neurology, January 24, 2006; 66(1_suppl_1): S30 - S32. [Abstract] [Full Text] [PDF]

Correspondence: